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SUMMARY Desmosomal cadherins in humans involve three iso-
forms, each in two splicing variants, of desmocollin (DSC1-3) and 
four isoforms of desmoglein (DSG1-4). DSGs are transmembranous 
desmosomal adhesive glycoproteins, which are generally expressed 
in a differentiation-specific manner. The aim of this study was to 
measure intensities of expression of both DSG2 and DSG3 in basal 
cell carcinoma (BCC) and to compare them with those in normal 
epidermis. Using immunoperoxidase staining on frozen tissue with 
monoclonal antibodies against human DSG2 and DSG3, DSG2 and 
DSG3 expression was assessed in specimens from 26 BCC patients. 
There was a significant overexpression of DSG2 and a significantly 
lower expression of DSG3 in BCC tumor nests (BCCpos) compared 
to non-BCC-affected epidermis (BCCneg). There was no significant 
correlation between the intensities of DSG2 and DSG3 expression in 
BCCpos, but there was a significant correlation (r=+0.6092) between 
these markers in BCCneg. That loss of coordination of DSG2 and DSG3 
expression in BCC, revealed with quantitative digital morphometry, 
might explain in part the BCC behavior as a locally invasive tumor. 
Our study further suggests that in human skin, DSG2-mediated ad-
hesion appears to be more proliferation-associated, whereas DSG3-
mediated adhesion seemingly is more differentiation-associated.
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INTRoDUCTIoN
Desmosomes form the intercellular junctional com-
plex, essential for maintaining tissue integrity. They 
participate in a number of pathologic processes includ-
ing tumor formation, invasion and metastasis (1). Des-
mosomal cadherins in humans involve three isoforms, 
each in two splicing variants, of desmocollin (DSC1-3) 
*The study was presented as a poster at the 40th Annual ESDR Meeting (September 8-11, 2010, Helsinki, Finland), and published in the abstract 
form: Bowszyc Dmochowska M, Gornowicz J, Seraszek A, Kaczmarek E, Dmochowski M. Quantitative digital morphometry reveals decreased 
expression of desmoglein 3, but increased expression of desmoglein 2, in basal cell carcinomas. J Invest Dermatol 2010;130 (Suppl 2):S23.
and four isoforms of desmoglein (DSG1-4). Each isoform 
arises from a different gene and has a characteristic ex-
pression pattern, which is dependent on tissue type 
and differentiation state (2,3). In some cases, the loss of 
DSGs in various types of carcinoma may be associated 
with an increased tumor cell capacity of migration (4).
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DSG1 and DSG3 are restricted to stratified epithe-
lia (5). DSG1 is more intensively expressed as the cells 
differentiate toward stratum corneum, and is very lit-
tle detectable in the basal layer, whereas DSG3 is local-
ized to the basal and immediate suprabasal layers (6). 
In normal human epidermis, DSG2 is expressed at low 
levels, and has been reported to be restricted to the 
lowermost epidermis (5). DSG2 expression fades with 
keratinocyte differentiation, whereas DSG3 expres-
sion decreases somewhat gradually from the basal 
into the spinous cell layers (3). DSG4 expression is re-
stricted to the highly differentiated upper cell layers 
(2). The distribution of DSGs in hair follicles has been 
described in some studies. Similar to epidermis, hair 
follicle is compartmentalized into a hierarchy of cell 
types based on the level of differentiation (6). DSG1 is 
expressed in the inner root sheath and the innermost 
layers of the outer root sheath. There is a report that 
DSG2 is highly expressed by the least differentiated 
cells of the cutaneous epithelium, including the hair 
follicle bulge of the fetus and adult, bulb matrix cells, 
and basal layer of the outer root sheath (6). Expres-
sion of DSG3 in hair follicle is correlated with differ-
ent types of keratinization (all layers of the outer root 
sheath in the areas of trichilemmal keratinization and 
mainly basal layer in the areas of epidermal-like ke-
ratinization) (6). DSG4 is expressed specifically in the 
hair shaft cortex, lower hair cuticle, and upper inner 
root sheath cuticle (7). Probably this molecule is a key 
mediator of keratinocyte cell adhesion in hair follicle, 
where it coordinates transition from proliferation to 
differentiation (5). 
Recent studies have suggested that bulge region 
might be a reservoir of stem cells of hair follicles (8,9). 
Hair follicle stem cells are multipotent and have a su-
perior clonogenicity and proliferative capacity. They 
are capable of giving rise to all cell types of hair, epi-
dermis and sebaceous gland (6,8,9). Bulge cells might 
be susceptible to genetic alteration and be a source 
of carcinogenic mutations (9). Some data suggest 
that several skin tumors including basal cell carci-
noma (BCC) might be derived from hair follicle cells, 
particularly bulge cells (9). 
Basal cell carcinoma is one of the most frequent 
types of cancer in humans. It is usually slow growing 
and rarely metastasizes; however, it can cause clini-
cally significant local destruction and disfigurement 
when neglected or inadequately treated (10,11). The 
growth of BCC is usually localized to the area of its ori-
gin; nevertheless, disturbance of adhesion should be 
regarded as a feature of its pathogenesis (12). Clinical 
appearances and morphology are diverse (11). Basal 
cell carcinomas have many traditional histopatholog-
ic subtypes, depending on the predominating pat-
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tern, including the following (13): solidum, adenoides, 
cysticum, keratoticum, pigmentosum, superficiale, cica-
trisans, styloides, and their combinations.
There is some evidence that BCC etiology is de-
pendent on several signaling pathways, like hedge-
hog, Wnt signaling and MAPK pathway (11). Litera-
ture data suggest that overexpression of desmosom-
al marker, DSG2, can deregulate multiple signaling 
pathways associated with the development of skin 
tumors (14).
The aim of this study was to measure intensities 
of expression of both DSG2 (apparently not pemphi-
gus autoantigen) and DSG3 (known pemphigus au-
toantigen) in BCC, and to compare them with those 
in normal epidermis in order to simultaneously assess 
the role of DSG2 and DSG3, both adhesive molecules, 
in differentiation and proliferation of keratinocytes 
in physiological and pathological (local malignancy) 
conditions in humans. 
MATERIAL AND METHoDS
The study included 26 patients (18 men and 8 
women) with various histologic subtypes of BCC, 
diagnosed and treated at Department of Dermatol-
ogy, Poznan University of Medical Sciences in Poland 
between November 2009 and July 2010. Expression 
of DSG2 and DSG3 was evaluated in BCC tumor nests 
(BCCpos) irrespectively of the BCC histologic sub-
type, and in non-BCC-affected epidermis (BCCneg) 
in patients with BCC. Conventional hematoxylin and 
eosin staining was performed in all cases to estab-
lish the diagnosis. The appropriate immunohisto-
chemical procedure controls were performed. Frozen 
specimens had to be used for immunohistochemistry 
throughout the study because attempts with paraf-
fin-embedded specimens for DSG3 visualization un-
der various conditions proved futile.
The study of expression of DSG2 and DSG3 was 
performed on frozen tissues subjected to 4-µm cryo-
sectioning and then mounted on poly-L-lysine coated 
glass slides. DSG2 and DSG3 were detected with the 
use of monoclonal murine antibodies (anti-DSG2 from 
AbD Serotec, UK) (anti-DSG3 from Invitrogen, USA, 
immunogen was human DSG3 extracellular domain). 
The slides were incubated with an appropriate dilu-
tion of antibodies at room temperature for 1 hour.
To visualize immunoreactivity, the sections were 
treated with LSAB+ system+ HRP visualization kit 
(Dako, Denmark). Then the slides were washed with 
PBS, counterstained with hematoxylin, coverslipped, 
and examined by light microscopy (BX40, Olympus, 
Japan) under magnification x400 and digitally photo-
graphed (Fig. 1A,B and Fig 2A,B).
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We used the quantitative morphometric software 
(Amiga Analyser 4D, Poland) to evaluate quantitative-
ly the positive immunostaining signals of DSG2 and 
DSG3 in BCCpos and in BCCneg serving as an internal 
control (Fig. 1C,D and Fig. 2C,D). Expression of these 
proteins in BCCpos and BCCneg on serial sections 
was measured in percentage of DSG2/DSG3 reaction 
(area of positive reaction divided by area studied and 
then multiplied by 100).
Statistical analysis was done using Wilcoxon test 
(DSG2 versus DSG3) and Mann-Whitney test (DSG2 in 
BCCpos versus DSG2 in BCCneg and DSG3 in BCCpos 
versus DSG3 in BCCneg). Correlation between DSG2 
and DSG3 expression in BCCpos and BCCneg was cal-
culated using Spearman’s rank correlation coefficient. 
All analyses were performed using the Statistica PL 
8.0 StatSoft statistical software. 
RESULTS
Results are shown in Table 1 and Figures 1-4. On 
quantitative analysis of immunohistochemical exam-
ination, the expression of DSG2 and DSG3 showed 
differences between BCCpos and BCCneg. There was 
a significant overexpression of DSG2 and significant-
ly lower expression of DSG3 in BCCpos compared to 
BCCneg (Table 1). In immunohistochemical study, 
most of the BCCneg areas were negative or weakly 
positive for DSG2 staining, but strongly positive for 
DSG3 staining (Fig. 1). Conversely, the BCCpos areas 
mostly were positive for DSG2 staining and nega-
tive/weakly positive for DSG3 staining (Fig. 2).
Figure 4. Lack of correlation (r=+0.1822) between intensities 
of DSG2 and DSG3 expression (in percentage of DSG2/DSG3 
reaction) in BCC tumor nests (BCCpos). Trend line is shown.
Figure 1. Intense DSG3 expression (A) compared to 
low DSG2 expression (B) in non-BCC-affected epidermis 
(BCCneg) in a patient with BCC (immunoperoxidase stain-
ing on frozen sections); DSG3 expression (C) and DSG2 
expression (D) processed with digital microscopic image 
analysis in BCCneg. (original magnification x400)
Figure 2. Decreased DSG3 expression (A) and overexpres-
sion of DSG2 (B) in BCC tumor nests (BCCpos) (immunoper-
oxidase staining on frozen sections); DSG3 expression (C) 
and DSG2 expression (D) processed with digital microscop-
ic analysis in BCCpos. (original magnification x400)
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Figure 3. Significant correlation (r=+0.6092) between in-
tensities of DSG2 and DSG3 expression (in percentage 
of DSG2/DSG3 reaction) in non-BCC-affected epidermis 
(BCCneg). Trend line is shown.
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There was a significant correlation (r=+0.6092) 
between the intensities of DSG2 and DSG3 expres-
sion in BCCneg (Fig. 3), but no such correlation be-
tween these markers in BCCpos (r=+0.1822) (Fig. 4).
DISCUSSIoN
Our results showed clear difference in DSG2 and 
DSG3 expression between BCCpos on the one hand 
and BCCneg on the other. These results corroborate 
those of our previous studies (3,15). Some results of 
this study are also compatible with data obtained by 
Brennan et al. (14), who demonstrated an increased 
expression of DSG2 in malignant skin tumors. Analy-
sis of literature on molecular components of des-
mosomes and their association with tumorigenesis 
reveals that coordination of expression of these mol-
ecules in tumor cells is often altered. However, these 
data are still controversial. 
Findings obtained by Chen et al. (16), who dem-
onstrated the expression of DSG3 in normal oral ke-
ratinocytes to be very low in contrast to high levels of 
expression in head and neck cancer cells, are incom-
patible with this view. Moreover, they found that 61% 
of patients with head and neck cancer studied had 
DSG3 protein overexpression in tumor tissues com-
pared to paired grossly normal counterparts. Similar-
ly, Chi-Che et al. (1) report on overexpression of DSG3 
in inverted papilloma (IP) and IP with squamous cell 
carcinoma (SCC). This group of researchers has also 
demonstrated that this overexpression correlated 
with malignant transformation of IP. Moreover, at the 
transcriptional level of DSG3, overexpression was ob-
served in pulmonary SCCs, but in adenocarcinomas 
the expression was very limited (17). Also, their re-
sults do not corroborate the finding by Shirakata et 
al. (18), who demonstrated DSG3 to be the predomi-
nant desmoglein isoform in both keratinizing and 
non-keratinizing oral epithelia. Therefore, it might be 
advantageous to analyze DSG3 expression more thor-
oughly, as its levels apparently do show significant 
variations in different types of carcinoma. To resolve 
this issue, we suggest using a wider scope of investi-
gated sample materials in respect to both the type of 
carcinoma and the cells assessed (oral keratinocytes 
versus skin keratinocytes), as well as different clones 
of the monoclonal antibodies to DSG3 which would 
be capable of recognizing various epitopes of a pro-
tein undergoing posttranslational modifications. 
During the last decade, the expression of cadher-
ins and desmosomal proteins during tumor progres-
sion has been subjected to extensive studies, the 
majority of which have been focused on the role of 
E-cadherin. The loss of E-cadherin expression and/
or function has been observed during tumor pro-
gression of most carcinomas (19). Kurzen et al. (20) 
found no qualitative correlation of desmoplakin or 
plakoglobin expression with the risk of metastasis in 
SCC of the skin. On the other hand, many literature 
reports have documented alterations in the expres-
sion of desmosomal cadherins during the process 
of tumorigenesis (21). Recent studies have shown 
the loss of DSG2 in gastric cancer (22,23), DSC2 in 
colorectal cancer (24) and DSC3 in breast cancer (25). 
In contrast to gastric cancer, DSG2 was overexpressed 
in both SCC of the skin (18) and in BCC (26). Tada et al. 
(27) semiquantitatively analyzed immunofluorescent 
images suggesting that the expression of DSG1 and 
plakoglobin is markedly reduced or absent in both 
SCC and BCC tumor cells (27). Goyal et al. have re-
cently reported no statistically significant difference 
in the expression of E-cadherin and catenins (α-, β-, γ-
catenin) in the paired normal background and tumor 
tissues (human breast cancer) (28). Some studies (29) 
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demonstrated that down-regulated expression of E-
cadherin, catenins and p120 occurs frequently in he-
patocellular carcinomas. Future research may show 
whether the expression levels of certain desmosomal 
protein coding genes, or perhaps an expression level 
network of many genes might serve as a new bio-
marker of tumorigenesis. 
Furthermore, hair follicles, which physiologically 
express DSGs, apparently are involved in both pem-
phigus pathogenesis and BCC pathogenesis (15). Par-
ticularly, bulge cells are in the area of research inter-
est because of their possible role in tumorigenesis (9), 
including that of BCC. Several research groups have 
noted that some BCCs express K-15 that is usually ex-
pressed in human follicle bulge cells (9). Interestingly, 
it has been found that overexpression of Shh gene 
(sonic hedgehog), a gene essential for hair follicle 
morphogenesis, resulted in the formation of BCC-
like tumors (9). However, Youssef et al. (30) have very 
recently revealed that BCC does not originate from 
bulge stem cells, as previously thought. With the use 
of clonal analysis in a mouse model of the disease, 
they found that BCC arised from long-term resident 
progenitor cells of the interfollicular epidermis and 
upper infundibulum (30). Still, DSGs can be important 
in BCC pathogenesis regardless of the issue of BCC 
cellular origin, as they are expressed in both bulge 
region and upper infundibulum of the hair follicle 
and interfollicular epidermis. Furthermore, analyzing 
DSGs expression patterns in relation to various his-
tologic subtypes of BCC might help clarify the issue 
of differences in the biological behavior of these BCC 
subtypes. 
CoNCLUSIoN
Thus, our results seem to indicate that both DSG2 
and DSG3 might be involved in BCC pathogenesis. 
Seemingly, the expression of DSG2 and DSG3, adhe-
sion molecules that plausibly play different roles in 
proliferation and differentiation of epidermis, is coor-
dinated in BCCneg, but this apparent coordination is 
lost in BCCpos. That loss of coordination of DSG2 and 
DSG3 expression, revealed with quantitative digital 
morphometry, in BCC might in part explain BCC be-
havior as a locally invasive tumor.
There is still a very interesting issue of what role 
desmosomal adhesion and desmosomal compo-
nents (particularly DSGs) play in carcinogenesis. The 
disturbance of desmosomal adhesion can result 
in tissue integrity damage and possibly induction 
of tumor cell migration and proliferation. Our BCC 
study, in which both physiological and pathological 
expression of both DSG2 and DSG3 was statistically 
compared using quantitative digital morphometry 
further suggests that in human skin DSG2-mediated 
adhesion appears to be more proliferation-associ-
ated, whereas DSG3-mediated adhesion seemingly is 
more differentiation-associated.
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